Ernexa Therapeutics Inc.
$0.19
▼
-4.75%
2026-04-21 06:41:01
www.ernexatx.com
NCM: ERNA
Explore Ernexa Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.87 M
Current Price
$0.19
52W High / Low
$4.05 / $0.18
Stock P/E
—
Book Value
$0.31
Dividend Yield
0.34%
ROCE
-342.48%
ROE
-6.87%
Face Value
—
EPS
$-2.24
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
5
Beta
6.85
Debt / Equity
20.41
Current Ratio
1.01
Quick Ratio
1.01
Forward P/E
-0.02
Price / Sales
—
Enterprise Value
$4.3 M
EV / EBITDA
-0.46
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Longeveron Inc. | $1.04 | — | $25.59 M | — | -377.18% | -1.65% | $1.83 / $0.47 | $0.25 |
| 2. | Enliven Therapeutics, Inc. | $46.41 | — | $2.88 B | — | -26.04% | -26.95% | $48.53 / $14.79 | $7.73 |
| 3. | Immunic, Inc. | $0.95 | — | $124.59 M | — | 1572.16% | -16.53% | $1.51 / $0.51 | $-0.06 |
| 4. | Ginkgo Bioworks Holdings, Inc. | $7.98 | — | $492.71 M | — | -29.68% | -51.08% | $17.58 / $5.37 | $8.74 |
| 5. | GeoVax Labs, Inc. | $1.17 | — | $3.38 M | — | -498.05% | -3.77% | $34.75 / $1.14 | $4.13 |
| 6. | Xilio Therapeutics, Inc. | $8.45 | — | $49.46 M | — | -42.66% | -1.33% | $16.52 / $6.47 | $7.79 |
| 7. | ARS Pharmaceuticals, Inc. | $8.18 | — | $812.25 M | — | -62.2% | -92.33% | $18.9 / $6.66 | $1.15 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.09 M | -1.99 M | -2.5 M | -2.73 M | -2.7 M | — |
| Net Profit | -1.5 M | -1.24 M | -3.14 M | -8.2 M | -5.76 M | — |
| EPS in Rs | -0.05 | -0.04 | -0.11 | -0.28 | -0.2 | -73.7 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0.58 M | 0.07 M | 0 M |
| Operating Profit | -9.32 M | -17.25 M | -20.68 M | -26.95 M |
| Net Profit | -14.08 M | -44.54 M | -21.67 M | -24.58 M |
| EPS in Rs | -0.48 | -1.53 | -0.74 | -0.84 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 5.83 M | 5.27 M | 49.13 M | 22.28 M |
| Total Liabilities | 3.43 M | 3.57 M | 46.9 M | 10.17 M |
| Equity | 2.4 M | 1.7 M | 2.23 M | 12.11 M |
| Current Assets | 3.13 M | 2.35 M | 9.6 M | 13.68 M |
| Current Liabilities | 3.11 M | 2.94 M | 6.57 M | 7.65 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -7.02 M | -15.84 M | -20.41 M | -20.98 M |
| Investing CF | -0.04 M | -0.36 M | -0.02 M | -0.05 M |
| Financing CF | 7.21 M | 6.26 M | 16.56 M | 19.58 M |
| Free CF | -7.05 M | -16.2 M | -20.43 M | -21.27 M |
| Capex | -0.04 M | -0.37 M | -0.02 M | -0.3 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 755.88% | — | — | — |
| Earnings Growth % | -105.55% | 11.84% | — | — |
| Profit Margin % | -7652.75% | -31864.71% | — | — |
| Operating Margin % | -2963.92% | -30404.41% | — | — |
| Gross Margin % | 83.51% | -247.06% | — | — |
| EBITDA Margin % | -6206.01% | -29314.71% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-06-12 | 1:0.0666667 |
| 2022-10-17 | 1:0.05 |